Anti-interleukin-6 agents are a class of therapeutics. Interleukin 6 is a cytokine relevant to many inflammatory diseases and many cancers. [1] . Hence, anti-IL6 agents have been sought. [2][3][4][5][6] In rheumatoid arthritis they can help patients unresponsive to TNF inhibitors. [7]

Jul 9, 2024 · Multiple pharmacologic inhibitors (sometimes termed blockers) of IL-6 are commercially available for clinical use, including monoclonal antibodies directed against the IL-6 receptor (IL-6R; eg, tocilizumab, sarilumab, and satralizumab) as well as monoclonal antibodies specific for IL-6 (eg, siltuximab and olokizumab).

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.

Interleukin inhibitors are immunosuppressive agents which inhibit the action of interleukins. Interleukins are a group of cytokines which are synthesized by lymphocytes, monocytes, macrophages, and certain other cells. They function especially in regulation of …

Sep 4, 2014 · For this reason, tocilizumab, a humanized anti-IL-6 receptor antibody was developed. Various clinical trials have since shown the exceptional efficacy of tocilizumab, which resulted in its approval for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis.

Apr 23, 2020 · To mark the tenth anniversary of anti-IL-6 receptor therapy worldwide, we discuss the history of research into IL-6 biology and the development of therapies that target IL-6 signalling,...

IL-6 receptor blockers target and block the IL-6 receptor, preventing IL-6 from binding to it. IL-6 is a key player in the immune response and inflammation. In conditions like rheumatoid arthritis, elevated IL-6 levels contribute to chronic inflammation, pain, and joint damage.

Dec 12, 2020 · In this article, we present a systematic review and meta-analysis on the efficacy of anti-IL-6 receptor (anti-IL-6R) antibody in neutralizing IL-6 by evaluating the reduction of the C-reactive protein (CRP) inflammatory marker, clinical outcomes, and the adverse events among severe COVID-19-infected patients.

Siltuximab is an anti-IL-6 immunoglobulin G-k monoclonal antibody that specifically binds to IL-6 and neutralizes its biological activity; it was approved in the USA in 2014 with restriction to the treatment of Castleman disease (Lyseng-Williamson, 2015).

IL-6 is involved both in immune responses and in inflammation, hematopoiesis, bone metabolism and embryonic development. IL-6 plays roles in chronic inflammation (closely related to chronic inflammatory diseases, autoimmune diseases and cancer) and even in the cytokine storm of corona virus disease 2019 (COVID-19).